We unite strategic go-to-market advisory with a license-ready commercial platform to de-risk entry, accelerate patient access, and help you retain full control.
Mirava Bio’s integrated platform and seasoned team streamline entry into EMEE markets, reducing lead times and maximizing biotech valuation.
Partners retain authority over pricing, commercialization strategy, and critical decisions while leveraging Mirava Bio’s infrastructure
Mirava’s advanced digital platform ensures seamless management of the product lifecycle, enhancing efficiency and decision-making.
With deep experience of rare disease therapies, Mirava Bio offers tailored strategies to overcome unique market challenges.
Flexible services that grow with your needs, adapting to the demands of rare disease commercialization at every stage. The same partner, from day 1 to the LCM of your product(s)
A fully flexible model that minimizes risk and upfront costs while optimizing efficiency — letting you retain full control and ownership.
Mirava Bio is building a fully licensed commercial organization ready (WDA, GDP) to enable compliant ATMP and rare disease drug commercialization. Applications are underway, and we adapt our licensing portfolio to match product profiles, expanding as needed to ensure seamless market entry.